El Aatmani Mohamed, Poujol Sylvain, Astre Cecile, Malosse Françoise, Pinguet Frederic
Department of Pharmacy, Val d'Aurelle Anticancer Center, Montpellier, France.
Am J Health Syst Pharm. 2002 Jul 15;59(14):1351-6. doi: 10.1093/ajhp/59.14.1351.
The stability of dacarbazine in commercial glass vials and polyvinyl chloride (PVC) bags in various storage conditions and the emergence of 2-azahypoxanthine, a major degradation product possibly linked with some adverse effects, were studied. Triplicate samples of reconstituted (11 mg/mL) and diluted (1.40 mg/mL) dacarbazine admixtures were prepared and stored at 4 degrees C or at 25 degrees C in daylight, fluorescent light, or the dark. The effect of several light-protective measures (amber glass vials, aluminum foil wrapping, and opaque tubing) on dacarbazine stability in a simulated i.v. infusion system was also evaluated. Dacarbazine quantification and main degradation product determination were performed by high-performance liquid chromatography. Stability was defined as conservation of 90-105% of initial dacarbazine concentration without major variations in clarity, color, or pH and without precipitate formation. Reconstituted dacarbazine solutions were stable for 24 hours at room temperature and during light exposure and stable for at least 96 hours at 2-6 degrees C when stored in the dark. After dilution in PVC bags, stability time increased from 2 hours in daylight to 24 hours in fluorescent light and to 72 hours when covered with aluminum foil. After two hours of simulated infusion, dacarbazine remained stable. Diluted dacarbazine solutions stored at 2-6 degrees C were stable for at least 168 hours. The only degradation product found was 2-azahypoxanthine, which was detected in every sample. The storage and handling of dacarbazine should take into account both the loss of the drug and the production of its potentially toxic degradation product. Dacarbazine must be carefully protected from light, administered using opaque infusion tubing, and, if necessary, refrigerated before administration to reduce 2-azahypoxanthine formation.
研究了达卡巴嗪在不同储存条件下于商用玻璃瓶和聚氯乙烯(PVC)袋中的稳定性,以及2-氮杂次黄嘌呤(一种可能与某些不良反应有关的主要降解产物)的出现情况。制备了复溶(11 mg/mL)和稀释(1.40 mg/mL)的达卡巴嗪混合液的一式三份样品,并在4℃或25℃下于日光、荧光或黑暗环境中储存。还评估了几种光保护措施(琥珀色玻璃瓶、铝箔包裹和不透明输液管)对模拟静脉输液系统中达卡巴嗪稳定性的影响。通过高效液相色谱法进行达卡巴嗪定量和主要降解产物测定。稳定性定义为初始达卡巴嗪浓度保持在90 - 105%,澄清度、颜色或pH无重大变化且无沉淀形成。复溶的达卡巴嗪溶液在室温及光照下稳定24小时,在2 - 6℃黑暗中储存时稳定至少96小时。在PVC袋中稀释后,稳定性时间从日光下的2小时增加到荧光下的24小时,用铝箔覆盖时增加到72小时。经过两小时模拟输注后,达卡巴嗪仍保持稳定。在2 - 6℃储存的稀释达卡巴嗪溶液稳定至少168小时。发现的唯一降解产物是2-氮杂次黄嘌呤,在每个样品中均检测到。达卡巴嗪的储存和处理应同时考虑药物损失及其潜在有毒降解产物的产生。达卡巴嗪必须小心避光,使用不透明输液管给药,如有必要,给药前冷藏以减少2-氮杂次黄嘌呤的形成。